A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 20284 participants.

Also called NCT05757869

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 20,284 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05757869
  • EU CT 2022-501419-15-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05757869. Randomized; double masking; primary purpose treatment. Start 2023-04-11 (actual); primary completion 2026-12-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Acronym
LIBREXIA-AF
Intervention (Drug)
Milvexian
Intervention (Drug)
Apixaban
Intervention (Drug)
Placebo
Intervention (Drug)
Apixaban Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct05757869
Content hash
39aa9854d592da7361e5b4e883b9f76fe96e7156f7b4de57164f192ac362b89d